Deltex Medical has raised £1.4m in new capital to launch, market and commercialise the next generation TrueVue haemodynamic monitor as well as a new non-invasive ultrasound probe. Each product has a significant potential to accelerate revenue growth for the Company, from a capital replacement perspective, but also to grow the addressable market and raise market penetration
